Georgia Dimopoulou

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project

Stephen P. Finn, Alfredo Addeo, Urania Dafni et al. · Journal of Thoracic Oncology · 2021 · 64 citations · Full text

Medicine, Genetics, Oncology +14

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)

Nathan I. Cherny, Sjoukje F. Oosting, Urania Dafni et al. · Annals of Oncology · 2025 · 53 citations · Full text

Pharmacy, Psychology, Outcomes Research +7

COVID-19 and the Global Impact on Colorectal Practice and Surgery

Joseph W. Nunoo‐Mensah, Mariam Rizk, Philip F. Caushaj et al. · Clinical Colorectal Cancer · 2020 · 34 citations · Full text

Medicine, Infectious Diseases, Surgery +14

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

Anna S. Berghoff, Cristiana Sessa, Jie Yang et al. · ESMO Open · 2021 · 25 citations · Full text

Medicine, Leadership, Oncology +13